PROGRAM MANAGER: Jonathan Jakischa
OPPORTUNITY: Licensing, product acquisition, joint development, supplier agreement
Phase 1 – Proof of concept (6-9 months)
Phase 2 – Development and implementation (9-12 months)
Phase 1 – Proof of concept funding will be commensurate with the nature and scope of work proposed.
Phase 2 – Additional funding to be negotiated based on outcome of Phase 1 and level of activity or licensing required for further development.
SOLUTION PROVIDER HELP DESK:
NineSigma, representing the Altria Group, invites proposals for technologies that will enable high throughput sampling from tissue cultures.
NineSigma’s client, Altria, is interested in technology that supports high throughput sampling and sample tracking for tissue cultures. This technology would be used internally to support gene modification work. Altria would like to automate the process by which tissue cultures are sampled and evaluated. Ideal solutions will be able to take samples from an array of cultures in a way that allows the rest of the sample to continue growing. The tissue cultures to be sampled have an average surface area of roughly 0.25-0.5 cm2. Desired sample size is flexible and may range from 1mm2 up to ½ of the original culture size. The samples collected will be subject to PCR and subsequent sequencing.
The successful technology will:
Criteria for Moving from Phase 1 to Phase 2
Successful demonstration of the proposed technology in a client specified setting.
Approaches accompanied with strong supporting data are preferred. Conceptual solutions are not of interest.
Possible approaches might include, but are not limited to:
Responses from companies (small to large), academic researchers, other research institutes, consultants, venture capitalists, entrepreneurs, or inventors are welcome.
Appropriate responses will be submitted via the online Response Form and will address the following: